ACME Laboratories Ltd 2025 AR2
The report highlights ACME Laboratories Ltd.'s performance for the 2024-2025 fiscal year, emphasizing its commitment to the Triple Bottom Line of Profit, Planet, and People. The company achieved a 12.54% revenue growth and launched its first veterinary vaccine, LSD-NDOLL. A significant focus was placed on Zero Waste Farming, a regenerative agricultural model aimed at maximizing yields while minimizing environmental impact. ACME also advanced its Active Pharmaceutical Ingredients (API) project to reduce import dependency and celebrated the successful implementation of SAP S/4HANA for digital excellence.
Company: ACME Laboratories Ltd
Sector: Manufacturing
Country: Bangladesh
Year: 2025
Type: AR2
Pages: 220
Back to company
ACME Laboratories Ltd
Annual Report
The report highlights ACME Laboratories Ltd.'s performance for the 2024-2025 fiscal year, emphasizing its commitment to the Triple Bottom Line of Profit, Planet, and People. The company achieved a 12.54% revenue growth and launched its first veterinary vaccine, LSD-NDOLL. A significant focus was placed on Zero Waste Farming, a regenerative agricultural model aimed at maximizing yields while minimizing environmental impact. ACME also advanced its Active Pharmaceutical Ingredients (API) project to reduce import dependency and celebrated the successful implementation of SAP S/4HANA for digital excellence.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jul 1, 2024 - Jun 30, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Assurance
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees